State variation in the receipt of a contralateral prophylactic mastectomy amongwomen who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004-2012

JAMA Surgery

Volumn 152, Issue 7, 2017, Pages 648-657

  Nash, Rebecca ^a   Goodman, Michael ^a   Lin, Chun Chieh ^b   Freedman, Rachel A ^c   Dominici, Laura S ^d   Ward, Kevin ^a   Jemal, Ahmedin ^b  

^a EMORY UNIVERSITY   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; BREAST NEOPLASMS; BREAST RECONSTRUCTION; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMAN; MIDDLE AGED; PATHOLOGY; PROPHYLACTIC MASTECTOMY; REGISTER; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MAMMAPLASTY; MIDDLE AGED; NEOPLASM STAGING; PROPHYLACTIC MASTECTOMY; REGISTRIES; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 85021124358     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2017.0115     Document Type: Article

References (58)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
2. Pesce CE, Liederbach E, Czechura T, Winchester DJ, Yao K. Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: A report from the National Cancer Data Base. J Am Coll Surg. 2014;219(1):19-28.
3. Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27(9):1362-1367.
4. Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: A report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol. 2010;17(10):2554-2562.
5. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102(6):401-409.
6. Brewster AM, Bedrosian I, Parker PA, et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012;118(22): 5637-5643.
7. Kurian AW, Lichtensztajn DY, Keegan THM, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA. 2014;312(9):902-914.
8. Pesce C, Liederbach E, Wang C, Lapin B, Winchester DJ, Yao K. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol. 2014;21(10):3231-3239.
9. Yao K, Winchester DJ, Czechura T, Huo D. Contralateral prophylactic mastectomy and survival: Report from the National Cancer Data Base, 1998-2002. Breast Cancer Res Treat. 2013;142(3): 465-476.
10. Hawley ST, Jagsi R, Morrow M, et al. Social and clinical determinants of contralateral prophylactic mastectomy. JAMA Surg. 2014;149(6):582-589.
11. Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: A cross-sectional survey. Ann Intern Med. 2013;159(6):373-381.
12. Fisher CS, Martin-Dunlap T, Ruppel MB, Gao F, Atkins J, Margenthaler JA. Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol. 2012;19 (10):3246-3250.
13. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203-5209.
14. National Cancer Institute. Surveillance, Epidemiology, and End Results Program: About the SEER Program. National Institutes of Health website. https://www.seer.cancer.gov/about. Accessed August 1, 2016.
15. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683-690.
16. Lerro CC, Robbins AS, Phillips JL, Stewart AK. Comparison of cases captured in the National Cancer Data Base with those in population-based central cancer registries. Ann Surg Oncol. 2013;20 (6):1759-1765.
17. Weir HK, Johnson CJ, Mariotto AB, et al. Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies. J Natl Cancer Inst Monogr. 2014;2014(49):198-209.
18. Young JL. SEER Summary Staging Manual, 2000: Codes and Coding Instructions. Bethesda, MD: Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute; 2006.
19. Johnson CH, ed. SEER Program Coding and Staging Manual 2004, Revision 1. Bethesda, MD: National Cancer Institute; 2004; NIH publication 04-5581.
20. Brown LD, Cai TT, Das Gupta A. Confidence intervals for a binomial proportion and asymptotic expansions. Ann Stat. 2002;30(1):160-201. doi:10 .1214/aos/1015362189
21. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3): 335-351.
22. Fu Y, Zhuang Z, Dewing M, Apple S, Chang H. Predictors for contralateral prophylactic mastectomy in breast cancer patients. Int J Clin Exp Pathol. 2015;8(4):3748-3764.
23. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158-2164.
24. Morrow M, Jagsi R, Alderman AK, et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA. 2009;302(14):1551-1556.
25. Nelson JA, Tchou J, Domchek S, Sonnad SS, Serletti JM, Wu LC. Breast reconstruction in bilateral prophylactic mastectomy patients: Factors that influence decision making. J Plast Reconstr Aesthet Surg. 2012;65(11):1481-1489.
26. Pinell-White XA, Kolegraff K, Carlson GW. Predictors of contralateral prophylactic mastectomy and the impact on breast reconstruction. Ann Plast Surg. 2014;72(6):S153-S157.
27. Yi M, Hunt KK, Arun BK, et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010;3(8):1026-1034.
28. Gold LS, Buist DS, Loggers ET, et al. Advanced diagnostic breast cancer imaging: Variation and patterns of care in Washington state. J Oncol Pract. 2013;9(5):e194-e202.
29. Sommer CA, Stitzenberg KB, Tolleson-Rinehart S, Carpenter WR, Carey TS. Breast MRI utilization in older patients with newly diagnosed breast cancer. J Surg Res. 2011;170(1):77-83.
30. Sorbero ME, Dick AW, Beckjord EB, Ahrendt G. Diagnostic breastmagnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol. 2009;16(6):1597-1605.
31. Stout NK, Nekhlyudov L, Li L, et al. Rapid increase in breastmagnetic resonance imaging use: Trends from 2000 to 2011. JAMA Intern Med. 2014; 174(1):114-121.
32. Wernli KJ, De Martini WB, Ichikawa L, et al; Breast Cancer Surveillance Consortium. Patterns of breastmagnetic resonance imaging use in community practice. JAMA Intern Med. 2014;174(1): 125-132.
33. Rosenberg SM, Ruddy KJ, Tamimi RM, et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol. 2016;2(6): 730-736.
34. Birkmeyer JD, Reames BN, Mc Culloch P, Carr AJ, Campbell WB, Wennberg JE. Understanding of regional variation in the use of surgery. Lancet. 2013;382(9898):1121-1129.
35. Chassin MR, Brook RH, Park RE, et al. Variations in the use of medical and surgical services by the Medicare population. N Engl J Med. 1986;314(5): 285-290.
36. Clemens J, Gottlieb JD. Do physicians' financial incentives affect medical treatment and patient health? Am Econ Rev. 2014;104(4):1320-1349.
37. Welch WP, Miller ME, Welch HG, Fisher ES, Wennberg JE. Geographic variation in expenditures for physicians' services in the United States. N Engl J Med. 1993;328(9):621-627.
38. Arriagada R, Lê MG, Rochard F, Contesso G; Institut Gustave-Roussy Breast Cancer Group. Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data. J Clin Oncol. 1996;14(5):1558-1564.
39. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16): 1233-1241.
40. Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med. 1995;332(14):907-911.
41. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232.
42. Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Engl J Med. 1992;326(17):1097-1101.
43. Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med. 1992;326(17):1102-1107.
44. Ridao-López M, Garciá-Armesto S, Abadiá-Taira B, Peiró-Moreno S, Bernal-Delgado E. Income level and regional policies, underlying factors associated with unwarranted variations in conservative breast cancer surgery in Spain. BMC Cancer. 2011;11:145.
45. Sariego J. Regional variation in breast cancer treatment throughout the United States. Am J Surg. 2008;196(4):572-574.
46. Smith GL, Xu Y, Shih YC, et al. Breast-conserving surgery in older patients with invasive breast cancer: Current patterns of treatment across the United States. J Am Coll Surg. 2009;209(4):425-433.e2.
47. Jerome-D'Emilia B, Begun JW. Diffusion of breast conserving surgery in medical communities. Soc Sci Med. 2005;60(1):143-151.
48. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646.
49. Yakoub D, Avisar E, Koru-Sengul T, et al. Factors associated with contralateral preventive mastectomy. Breast Cancer (Dove Med Press). 2015; 7:1-8.
50. Hawley ST, Griggs JJ, Hamilton AS, et al. Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. J Natl Cancer Inst. 2009;101(19):1337-1347.
51. Lee MK, Noh DY, Nam SJ, et al. Association of shared decision-making with type of breast cancer surgery: A cross-sectional study. BMC Health Serv Res. 2010;10:48.
52. Waljee JF, Rogers MA, Alderman AK. Decision aids and breast cancer: Do they influence choice for surgery and knowledge of treatment options? J Clin Oncol. 2007;25(9):1067-1073.
53. Kane HL, Halpern MT, Squiers LB, Treiman KA, Mc Cormack LA. Implementing and evaluating shared decision making in oncology practice. CA Cancer J Clin. 2014;64(6):377-388.
54. Margenthaler JA, Ollila DW. Breast conservation therapy versus mastectomy: Shared decision-making strategies and overcoming decisional conflicts in your patients. Ann Surg Oncol. 2016;23(10):3133-3137.
55. Rosenberg SM, Sepucha K, Ruddy KJ, et al. Local therapy decision-making and contralateral prophylactic mastectomy in young women with early-stage breast cancer. Ann Surg Oncol. 2015;22 (12):3809-3815.
56. Katz SJ, Lantz PM, Janz NK, et al. Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol. 2005;23(24):5526-5533.
57. Boughey JC, Attai DJ, Chen SL, et al. Contralateral Prophylactic Mastectomy Consensus Statement from the American Society of Breast Surgeons: Additional considerations and a framework for shared decision making. Ann Surg Oncol. 2016;23(10):3106-3111.
58. Boughey JC, Attai DJ, Chen SL, et al. Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM outcomes and risks. Ann Surg Oncol. 2016;23(10):3100-3105.